Table 3.
Means of sitting diastolic and systolic blood pressure in nonresponders at Week 4 of high-dose treatment
| Visit | Fimasartan/HCTZ (N=74) |
Fimasartan (N=47) |
|
|---|---|---|---|
| siDBP (mmHg) | |||
| Week 4 | 97.93±5.64 | 97.28±4.64 | |
| Week 8 | 91.51±9.88 | 93.64±8.26 | |
| Change | −5.72±9.34 | −3.64±6.97 | |
| P-valuea | <0.0001 | 0.0008 | |
| P-valueb | 0.1922 | ||
| siSBP (mmHg) | |||
| Week 4 | 150.32±13.00 | 151.34±9.28 | |
| Week 8 | 142.46±16.64 | 149.89±12.67 | |
| Change | −7.86±15.40 | −4.45±11.45 | |
| P-valuea | <0.0001 | 0.0107 | |
| P-valueb | 0.1943 | ||
Notes: Data are expressed in mean ± SD.
a
Paired t-test between Week 4 and 8.
b
Two-sample t-test of blood pressure change between groups.
Abbreviations: HCTZ, hydrochlorothiazide; SD, standard deviation; siDBP, sitting diastolic blood pressure; siSBP, sitting systolic blood pressure.